Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data
Experimental Gerontology · 2025
DOI: 10.1016/j.exger.2025.112883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Gerontology, 2025. Verfasst von Meehee Park und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Sulfasalazine, Sarcopenia. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Ministry of SMEs and Startups, National Research Foundation of Korea.
Abstract (Originalsprache)
Sarcopenia, a disease marked by a progressive loss of muscle mass, increases the risks of disability and metabolic disorders, and decreases quality of life. Current therapeutic options are limited. YY1 transcriptional activity is augmented through an interaction with PHF20 at its promoter region, suppressing muscle differentiation. This study screened sulfasalazine, a medication for managing inflammatory bowel diseases (IBD), using the PHF20-YY1 promoter assay in C2C12 myoblasts from an FDA-approved drug library. Sulfasalazine effectively inhibited PHF20-induced YY1 promoter activity (IC50 = 24 μM), reducing YY1 expression and enhancing muscle-specific gene expression. In mouse models of muscle atrophy, sulfasalazine not only enhanced muscle strength and function but also mitigated muscle loss. Clinical data from patients with IBD revealed that those treated with sulfasalazine had a significantly higher TPI (total psoas index), used as a muscle mass marker, suggesting enhanced muscle preservation. In conclusion, this study suggests the potential for repurposing sulfasalazine to manage sarcopenia, especially associated with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon, Republic of Korea.
- Department of Surgery, Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon, Republic of Korea. Electronic address: basel97@mitos-thera.com.
- Mitos Biomedical Institute, Mitos Therapeutics Inc., Daejeon, Republic of Korea; Department of Pharmacology and Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea. Electronic…
Förderung
- Korea Ministry of SMEs and Startups
- National Research Foundation of Korea
Zitieren
APA
Park, M., Cho, S., Choi, S., Lee, H., Lee, J., Jo, Y., Park, J., & Park, J. (2025). Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data. Experimental Gerontology. https://doi.org/10.1016/j.exger.2025.112883
Vancouver
Park M, Cho S, Choi S, Lee H, Lee J, Jo Y, et al. Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data. Experimental Gerontology. 2025. doi:10.1016/j.exger.2025.112883
BibTeX
@article{Park2025,
author = {Park, Meehee and Cho, Seungju and Choi, Seonggyu and Lee, Hwayoung and Lee, Jandee and Jo, Youngsuk and Park, Jisoo and Park, Jongsun},
title = {Therapeutic potential of sulfasalazine for sarcopenia: Insights from mouse models and clinical data},
journal = {Experimental Gerontology},
year = {2025},
doi = {10.1016/j.exger.2025.112883}
}
EUVIMED